disopyramide has been researched along with Atrial Fibrillation in 117 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A single oral dose of pilsicainide (PLS) is effective in terminating acute-onset atrial fibrillation (AF)." | 9.09 | Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial. ( Abe, H; Hiraki, T; Ikeda, H; Imaizumi, T; Kumagai, K; Nakashima, H; Nakashima, Y; Oginosawa, Y; Saku, K, 2000) |
| "Safety and efficacy of propafenone and disopyramide for long-term maintenance of sinus rhythm after electrical cardioversion was studied in 56 patients with chronic atrial fibrillation (median arrhythmia duration, 5 months)." | 9.08 | Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. ( Crijns, HJ; Gosselink, AT; Lie, KI, 1996) |
| "The effects of disopyramide on the atrial fibrillation threshold (AFT) in the human atrium were investigated." | 9.08 | Effects of disopyramide on the atrial fibrillation threshold in the human atrium. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Sakai, R; Shirayama, T, 1995) |
| "Rhythm conversion in patients with post-thyrotoxic atrial fibrillation (AF) has been performed with disopyramide in order to evaluate the conversion rate and to test its effect on the maintenance of sinus rhythm after cardioversion." | 9.07 | Efficacy of disopyramide in conversion and prophylaxis of post-thyrotoxic atrial fibrillation. ( Ishikawa, N; Ito, K; Nakazawa, H; Noh, J; Ozaki, O; Sugimoto, T; Yashiro, T; Yoshimoto, M, 1991) |
| "In order to compare the efficacy in preventing recurrencies of symptomatic atrial fibrillation of amiodarone (A." | 9.07 | [A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation]. ( Locati, F; Nava, S; Veniani, M; Villani, R; Zoletti, F, 1992) |
| "In this multicentre study, 90 patients who left hospital in sinus rhythm after electroconversion of atrial fibrillation were randomized to double-blind treatment with either disopyramide (n = 44) or placebo (n = 46)." | 9.06 | Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. ( Abjörn, C; Jansson, SO; Karlson, BW; Peterson, LE; Torstensson, I, 1988) |
| "In order to compare the relative efficacy of quinidine, disopyramide and a placebo in the maintenance of sinus rhythm after cardioversion from atrial fibrillation and in order to examine the incidence of side-effects, 82 patients with continuous atrial fibrillation (duration more than 1 month but less than 3 years) were randomized in a double-blind fashion to receive quinidine, disopyramide or placebo." | 9.05 | The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo. ( Forman, R; Gersh, BJ; Lloyd, EA, 1984) |
| "The efficacy of sotalol in treating acute atrial fibrillation and flutter after open heart surgery was compared with that of a digoxin/disopyramide combination." | 9.05 | Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. ( Campbell, TJ; Gavaghan, TP; Morgan, JJ, 1985) |
| "Oral disopyramide given prophylactically following myocardial infarction has been compared with placebo in a double-blind trial using continuous-tape monoriting of the electocardiogram." | 9.04 | Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction. ( Besterman, EM; Jennings, G; Jones, MS; Kidner, PH; Model, DG; Turner, PP, 1976) |
| "Disopyramide (B 712) was tested in 39 patients with chronic arrhythmias of different kind: 23 cases with atrial fibrillation, 16 cases with ventricular ectopic beats, two cases with supraventricular tachycardias." | 9.04 | [Antiarrhythmic effect of disopyramide in ventricular extrasystole and auricular fibrillation]. ( Breithardt, G; Haerten, K; Seipel, L, 1976) |
| "Disopyramide, an antiarrhythmic drug, has been reported to cause hypoglycemia; however, its mechanism of action remains unclear." | 8.87 | Disopyramide-induced hypoglycemia in a non-diabetic hemodialysis patient: a case report and review of the literature. ( Abe, M; Fujii, Y; Kitai, M; Maruyama, T; Matsumoto, K; Okada, K; Soma, M, 2011) |
| "Atrial pacing failure occurred after termination of atrial fibrillation by acute administration of disopyramide phosphate in a 71-year-old woman implanted with an AAI pacemaker for sick sinus syndrome." | 7.73 | Atrial pacing failure following termination of atrial fibrillation by acute administration of disopyramide phosphate. ( Anzawa, R; Ishikawa, S; Mochizuki, S; Okazaki, F; Tanaka, Y, 2005) |
| "We studied changes in atrial pacing threshold after termination of atrial fibrillation (AF) by acute administration of disopyramide phosphate (DP) to elucidate the suitable setting for atrial pacing output before AF termination." | 7.73 | Increased AAI mode pacing threshold after termination of atrial fibrillation by acute administration of disopyramide phosphate. ( Anzawa, R; Ishikawa, S; Mochizuki, S; Okazaki, F; Tanaka, Y, 2006) |
| "The relationship between the efficacy of the anticholinergic action of disopyramide, cibenzoline and aprindine and age was examined in patients with paroxysmal and persistent atrial fibrillation." | 7.72 | [Comparison of the efficacies of disopyramide, cibenzoline and aprindine for the termination of paroxysmal and persistent atrial fibrillation in elderly and non-elderly patients]. ( Abe, N; Horiuchi, D; Kameda, K; Komatsu, T; Nakamura, S; Oikawa, K; Okumura, K; Owada, S; Suzuki, O; Tomita, H; Yomogida, K, 2003) |
| "The relationship between the duration of arrhythmia and the subsequent long-term efficacy of disopyramide in preventing atrial fibrillation was investigated in patients with symptomatic paroxysmal and persistent atrial fibrillation." | 7.72 | [Relationship between duration of arrhythmia and subsequent preventive effect of disopyramide after cardioversion in patients with symptomatic paroxysmal and persistent atrial fibrillation]. ( Abe, N; Horiuchi, D; Kameda, K; Komatsu, T; Nakamura, S; Oikawa, K; Okumura, K; Owada, S; Suzuki, O; Tomita, H; Yomogida, K, 2003) |
| " The purpose of this present study was to test whether P-SAECG mapping system would give any information on the efficacy of disopyramide on the prevention of paroxysmal atrial fibrillation (PAF)." | 7.70 | Dispersion of filtered P wave duration by P wave signal-averaged ECG mapping system: its usefulness for determining efficacy of disopyramide on paroxysmal atrial fibrillation. ( Hiraki, T; Ikeda, H; Imaizumi, T; Kubara, I; Ohga, M; Yoshida, T, 1999) |
| " The patient had been treated with disopyramide (50 mg/day) because of paroxysmal atrial fibrillation." | 7.70 | Hypoglycemia induced by interaction between clarithromycin and disopyramide. ( Iida, H; Iwasawa, K; Morita, T; Nakajima, T; Suzuki, E; Toyo-oka, T, 1999) |
| "Combined administration of propranolol and disopyramide treatment often leads to better results in patients with atrial fibrillation refractory to only disopyramide administration." | 7.70 | [Electrophysiological mechanism of combination therapy with disopyramide and propranolol for paroxysmal atrial fibrillation]. ( Annoura, M; Gondo, N; Kumagai, K; Saku, K; Yamanouchi, Y, 2000) |
| "We investigated whether the new parameter wavelength index could predict the response to chronic disopyramide therapy in patients with paroxysmal atrial fibrillation (AF)." | 7.69 | Wavelength index: a predictor of the response to disopyramide in paroxysmal lone atrial fibrillation. ( Annoura, M; Arakawa, K; Gondo, N; Hiroki, T; Kumagai, K; Matsuo, K; Moroe, K; Nakashima, Y, 1994) |
| "The effects of pilsicainide, a new class Ic antiarrhythmic agent, on the atrial fibrillation threshold (AFT), the atrial effective refractory period (ERP), and the interatrial conduction time (ACT) in Langendorff-perfused guinea pig hearts were investigated." | 7.68 | Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Omori, I; Sakai, R; Yamahara, Y, 1993) |
| "A study of the efficacy of intravenous disopyramide in the conversion of supraventricular tachyarrhythmias to sinus rhythm was undertaken in a group of 23 patients with a variety of cardiological diagnoses." | 7.67 | The use of intravenous disopyramide for the conversion of supraventricular tachyarrhythmias. ( Ikram, H; Stewart, DE, 1984) |
| "Electrophysiologic studies were performed before and after intravenous administration of disopyramide (2 mg/kg) to 40 patients with either documented or suspected atrial fibrillation (AF)." | 7.67 | Effect of disopyramide on initiation of atrial fibrillation and relation to effective refractory period. ( Hashimoto, J; Ito, M; Nagashima, M; Noshiro, H; Onodera, S; Shinoda, S; Suzuki, H, 1989) |
| "Disopyramide was administered intravenously to 54 patients during atrial fibrillation and predominantly pre-excited QRS configuration at the time of electrophysiologic study." | 7.67 | Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome. ( Fujimura, O; Klein, GJ; Sharma, AD; Szabo, T; Yee, R, 1989) |
| "The efficacy of verapamil and propranolol was studied in comparison with disopyramide on the atrial fibrillation experimentally induced in the dog heart in situ by electrical stimulation combined with intra-aortic injection of acetylcholine (ACh)." | 7.67 | Efficacy of disopyramide in comparison with verapamil and propranolol in the prevention of acetylcholine-induced atrial fibrillation in the dog. ( Bertrix, L; Bouzouita, K; Faucon, G; Lakhal, M; Lang, J; Timour Chah, Q, 1985) |
| "We evaluated the electrophysiologic effects of disopyramide phosphate in 12 patients with the Wolff-Parkinson-White syndrome." | 7.66 | Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome. ( Cook, L; Gallagher, JJ; Kerr, CR; Prystowsky, EN; Smith, WM, 1982) |
| "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes)." | 7.66 | Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide. ( Benhorin, J; Gottlieb, S; Keren, A; Stern, S; Tzivoni, D, 1982) |
| "The efficacy of intravenous disopyramide was studied during 200 episodes of supraventricular and ventricular arrhythmias in 160 patients, mainly presenting with acute myocardial infarction or cardiac failure." | 7.66 | Efficacy of intravenous disopyramide in acute cardiac arrhythmias. ( De Backer, M; Kahn, RJ; Stoupel, E, 1981) |
| "The effect of administration of disopyramide on the ventricular response to atrial fibrillation was studied in six patients with the Wolff-Parkinson-White syndrome." | 7.66 | Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. ( Bennett, DH, 1978) |
| "The probability of absence of recurrence at 6 months was 36 +/- 11% in Group C and 55 +/- 10% in Group D (p = NS)." | 6.69 | [A randomized double-blind trial comparing cibenzoline and disopyramide in the prevention of recurrences of atrial tachyarrhythmia]. ( Baudouy, Y; Bine-Scheck, F; Cheikel, J; Dambrine, P; Flammang, D; Graux, P; Jouannon, C; Leenhardt, A; Piot, O, 1998) |
| "Disopyramide was first infused intravenously at 1 mg kg-1 for 5 min followed by a continuous infusion at 0." | 5.28 | Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White syndrome. ( Aihara, N; Kamakura, S; Kurita, T; Matsuhisa, M; Ohe, T; Shimizu, W; Shimomura, K; Takaki, H, 1992) |
| "In the treatment of extrasystole, the arrhythmia was eliminated or reduced by 75% in 15 of 23 patients." | 5.26 | [Oral longterm therapy with disopyramide phosphate in patients with atrial and ventricular arrhythmias (author's transl)]. ( Grewe, N; Stauch, M, 1977) |
| "A single oral dose of pilsicainide (PLS) is effective in terminating acute-onset atrial fibrillation (AF)." | 5.09 | Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial. ( Abe, H; Hiraki, T; Ikeda, H; Imaizumi, T; Kumagai, K; Nakashima, H; Nakashima, Y; Oginosawa, Y; Saku, K, 2000) |
| "The effects of disopyramide on the atrial fibrillation threshold (AFT) in the human atrium were investigated." | 5.08 | Effects of disopyramide on the atrial fibrillation threshold in the human atrium. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Sakai, R; Shirayama, T, 1995) |
| "Safety and efficacy of propafenone and disopyramide for long-term maintenance of sinus rhythm after electrical cardioversion was studied in 56 patients with chronic atrial fibrillation (median arrhythmia duration, 5 months)." | 5.08 | Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. ( Crijns, HJ; Gosselink, AT; Lie, KI, 1996) |
| "Rhythm conversion in patients with post-thyrotoxic atrial fibrillation (AF) has been performed with disopyramide in order to evaluate the conversion rate and to test its effect on the maintenance of sinus rhythm after cardioversion." | 5.07 | Efficacy of disopyramide in conversion and prophylaxis of post-thyrotoxic atrial fibrillation. ( Ishikawa, N; Ito, K; Nakazawa, H; Noh, J; Ozaki, O; Sugimoto, T; Yashiro, T; Yoshimoto, M, 1991) |
| "In order to compare the efficacy in preventing recurrencies of symptomatic atrial fibrillation of amiodarone (A." | 5.07 | [A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation]. ( Locati, F; Nava, S; Veniani, M; Villani, R; Zoletti, F, 1992) |
| "In this multicentre study, 90 patients who left hospital in sinus rhythm after electroconversion of atrial fibrillation were randomized to double-blind treatment with either disopyramide (n = 44) or placebo (n = 46)." | 5.06 | Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. ( Abjörn, C; Jansson, SO; Karlson, BW; Peterson, LE; Torstensson, I, 1988) |
| "In order to compare the relative efficacy of quinidine, disopyramide and a placebo in the maintenance of sinus rhythm after cardioversion from atrial fibrillation and in order to examine the incidence of side-effects, 82 patients with continuous atrial fibrillation (duration more than 1 month but less than 3 years) were randomized in a double-blind fashion to receive quinidine, disopyramide or placebo." | 5.05 | The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo. ( Forman, R; Gersh, BJ; Lloyd, EA, 1984) |
| "The efficacy of sotalol in treating acute atrial fibrillation and flutter after open heart surgery was compared with that of a digoxin/disopyramide combination." | 5.05 | Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. ( Campbell, TJ; Gavaghan, TP; Morgan, JJ, 1985) |
| "Disopyramide (B 712) was tested in 39 patients with chronic arrhythmias of different kind: 23 cases with atrial fibrillation, 16 cases with ventricular ectopic beats, two cases with supraventricular tachycardias." | 5.04 | [Antiarrhythmic effect of disopyramide in ventricular extrasystole and auricular fibrillation]. ( Breithardt, G; Haerten, K; Seipel, L, 1976) |
| "Oral disopyramide given prophylactically following myocardial infarction has been compared with placebo in a double-blind trial using continuous-tape monoriting of the electocardiogram." | 5.04 | Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction. ( Besterman, EM; Jennings, G; Jones, MS; Kidner, PH; Model, DG; Turner, PP, 1976) |
| "Disopyramide, an antiarrhythmic drug, has been reported to cause hypoglycemia; however, its mechanism of action remains unclear." | 4.87 | Disopyramide-induced hypoglycemia in a non-diabetic hemodialysis patient: a case report and review of the literature. ( Abe, M; Fujii, Y; Kitai, M; Maruyama, T; Matsumoto, K; Okada, K; Soma, M, 2011) |
| " Most recently, the introduction of dofetilide has widened the therapeutic options in patients with severe heart disease, and the Canadian Trial of Atrial Fibrillation indicated the superior efficacy of amiodarone at low doses." | 4.82 | Antiarrhythmic drug therapy of atrial fibrillation. ( Mounsey, JP; VerNooy, RA, 2004) |
| "Among the drugs recommended to prevent recurrences of atrial fibrillation after external electric shock, antiarrhythmic agents of classes Ia (quinidine, disopyramide), Ic (cibenzoline, flecainide, propafenone) and III (sotalol) seem to have the same effectiveness in maintaining the sinus rhythm in about 50 percent of the cases after 6 months and one year." | 4.78 | [Antiarrhythmic treatment after reduction of atrial fibrillation by external shock]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Theolade, R, 1993) |
| " The purpose of this study was to assess the efficacy of the AADs disopyramide, quinidine, and propafenone on human atrial arrhythmias mediated by Pitx2-induced remodelling, from a single cell to the tissue level, using drug binding models with multi-channel pharmacology." | 4.02 | In Silico Assessment of Class I Antiarrhythmic Drug Effects on ( Bai, J; Gao, M; Lo, A; Lu, Y; Zhang, H; Zhao, J; Zhu, Y, 2021) |
| "Atrial pacing failure occurred after termination of atrial fibrillation by acute administration of disopyramide phosphate in a 71-year-old woman implanted with an AAI pacemaker for sick sinus syndrome." | 3.73 | Atrial pacing failure following termination of atrial fibrillation by acute administration of disopyramide phosphate. ( Anzawa, R; Ishikawa, S; Mochizuki, S; Okazaki, F; Tanaka, Y, 2005) |
| "We studied changes in atrial pacing threshold after termination of atrial fibrillation (AF) by acute administration of disopyramide phosphate (DP) to elucidate the suitable setting for atrial pacing output before AF termination." | 3.73 | Increased AAI mode pacing threshold after termination of atrial fibrillation by acute administration of disopyramide phosphate. ( Anzawa, R; Ishikawa, S; Mochizuki, S; Okazaki, F; Tanaka, Y, 2006) |
| "Disopyramide is thought to have an advantageous effect for atrial fibrillation (AF) associated with vagal activity because of its anticholinergic effect." | 3.73 | Heart rate variability is a useful parameter for evaluation of anticholinergic effect associated with inducibility of atrial fibrillation. ( Aizawa, Y; Chinushi, M; Hirono, T; Komura, S; Sugiura, H, 2005) |
| "The relationship between the efficacy of the anticholinergic action of disopyramide, cibenzoline and aprindine and age was examined in patients with paroxysmal and persistent atrial fibrillation." | 3.72 | [Comparison of the efficacies of disopyramide, cibenzoline and aprindine for the termination of paroxysmal and persistent atrial fibrillation in elderly and non-elderly patients]. ( Abe, N; Horiuchi, D; Kameda, K; Komatsu, T; Nakamura, S; Oikawa, K; Okumura, K; Owada, S; Suzuki, O; Tomita, H; Yomogida, K, 2003) |
| "The relationship between the duration of arrhythmia and the subsequent long-term efficacy of disopyramide in preventing atrial fibrillation was investigated in patients with symptomatic paroxysmal and persistent atrial fibrillation." | 3.72 | [Relationship between duration of arrhythmia and subsequent preventive effect of disopyramide after cardioversion in patients with symptomatic paroxysmal and persistent atrial fibrillation]. ( Abe, N; Horiuchi, D; Kameda, K; Komatsu, T; Nakamura, S; Oikawa, K; Okumura, K; Owada, S; Suzuki, O; Tomita, H; Yomogida, K, 2003) |
| " The atrial activation at the CT was determined during programmed stimulation with one extrastimulus at five pacing sites anteriorly to the CT in 10 patients with atrial flutter and 10 patients with atrial fibrillation before and after intravenous administration of 2 mg/kg disopyramide." | 3.70 | Transverse conduction capabilities of the crista terminalis in patients with atrial flutter and atrial fibrillation. ( Fischenbeck, C; Hagendorff, A; Jung, W; Lewalter, T; Lüderitz, B; Omran, H; Schmidt, H; Schumacher, B; Wolpert, C, 1999) |
| "Combined administration of propranolol and disopyramide treatment often leads to better results in patients with atrial fibrillation refractory to only disopyramide administration." | 3.70 | [Electrophysiological mechanism of combination therapy with disopyramide and propranolol for paroxysmal atrial fibrillation]. ( Annoura, M; Gondo, N; Kumagai, K; Saku, K; Yamanouchi, Y, 2000) |
| " The purpose of this present study was to test whether P-SAECG mapping system would give any information on the efficacy of disopyramide on the prevention of paroxysmal atrial fibrillation (PAF)." | 3.70 | Dispersion of filtered P wave duration by P wave signal-averaged ECG mapping system: its usefulness for determining efficacy of disopyramide on paroxysmal atrial fibrillation. ( Hiraki, T; Ikeda, H; Imaizumi, T; Kubara, I; Ohga, M; Yoshida, T, 1999) |
| " The patient had been treated with disopyramide (50 mg/day) because of paroxysmal atrial fibrillation." | 3.70 | Hypoglycemia induced by interaction between clarithromycin and disopyramide. ( Iida, H; Iwasawa, K; Morita, T; Nakajima, T; Suzuki, E; Toyo-oka, T, 1999) |
| "The effects of E-4031, a new class III antiarrhythmic agent, on atrial fibrillation threshold (AFT), atrial effective refractory period (ERP), and interatrial conduction time (ACT) were investigated in Langendorff-perfused guinea pig hearts; the results were then compared with those of the class I agents disopyramide, procainamide, lidocaine, and flecainide." | 3.69 | Effects of E-4031 on atrial fibrillation threshold in guinea pig atria: comparative study with class I antiarrhythmic drugs. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Sakai, R; Shirayama, T, 1994) |
| "Disopyramide as an antiarrhythmic can be prescribed to patients with atrial fibrillation and, owing to its negative inotropic effect, to patients with hypertrophic obstructive cardiomyopathy." | 3.69 | Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy. ( Horvat, M; Pernat, A; Pohar, B, 1997) |
| "We investigated whether the new parameter wavelength index could predict the response to chronic disopyramide therapy in patients with paroxysmal atrial fibrillation (AF)." | 3.69 | Wavelength index: a predictor of the response to disopyramide in paroxysmal lone atrial fibrillation. ( Annoura, M; Arakawa, K; Gondo, N; Hiroki, T; Kumagai, K; Matsuo, K; Moroe, K; Nakashima, Y, 1994) |
| "In order to determine the efficacy of type 1C agents (flecainide, encainide, propafenone) in patients with atrial fibrillation who have failed to maintain sinus rhythm with type 1A agents (quinidine, procainamide, disopyramide), 147 patients, that were admitted into the John Dempsey Hospital with new or recurrent atrial fibrillation between 1987-1991, were studied retrospectively." | 3.68 | Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation. ( Grey, E; Silverman, DI, 1993) |
| "The effects of pilsicainide, a new class Ic antiarrhythmic agent, on the atrial fibrillation threshold (AFT), the atrial effective refractory period (ERP), and the interatrial conduction time (ACT) in Langendorff-perfused guinea pig hearts were investigated." | 3.68 | Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Omori, I; Sakai, R; Yamahara, Y, 1993) |
| "A study of the efficacy of intravenous disopyramide in the conversion of supraventricular tachyarrhythmias to sinus rhythm was undertaken in a group of 23 patients with a variety of cardiological diagnoses." | 3.67 | The use of intravenous disopyramide for the conversion of supraventricular tachyarrhythmias. ( Ikram, H; Stewart, DE, 1984) |
| "Electrophysiologic studies were performed before and after intravenous administration of disopyramide (2 mg/kg) to 40 patients with either documented or suspected atrial fibrillation (AF)." | 3.67 | Effect of disopyramide on initiation of atrial fibrillation and relation to effective refractory period. ( Hashimoto, J; Ito, M; Nagashima, M; Noshiro, H; Onodera, S; Shinoda, S; Suzuki, H, 1989) |
| "Disopyramide was administered intravenously to 54 patients during atrial fibrillation and predominantly pre-excited QRS configuration at the time of electrophysiologic study." | 3.67 | Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome. ( Fujimura, O; Klein, GJ; Sharma, AD; Szabo, T; Yee, R, 1989) |
| "In this study, the safety and efficacy of long-term therapy with disopyramide phosphate were evaluated in 40 patients with documented, recurrent, symptomatic tachyarrhythmias." | 3.67 | Long-term therapy with disopyramide phosphate: side effects and effectiveness. ( Bauernfeind, RA; Bauman, JL; Gallastegui, J; Hoff, J; Strasberg, B; Swiryn, S; Welch, WJ, 1986) |
| "The efficacy of verapamil and propranolol was studied in comparison with disopyramide on the atrial fibrillation experimentally induced in the dog heart in situ by electrical stimulation combined with intra-aortic injection of acetylcholine (ACh)." | 3.67 | Efficacy of disopyramide in comparison with verapamil and propranolol in the prevention of acetylcholine-induced atrial fibrillation in the dog. ( Bertrix, L; Bouzouita, K; Faucon, G; Lakhal, M; Lang, J; Timour Chah, Q, 1985) |
| "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes)." | 3.66 | Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide. ( Benhorin, J; Gottlieb, S; Keren, A; Stern, S; Tzivoni, D, 1982) |
| ", verapamil, disopyramide, and procainamide, on paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (Af) and atrial flutter (AF) were evaluated electrophysiologically." | 3.66 | Electrophysiologic evaluation of antiarrhythmic drugs on supraventricular tachyarrhythmias. ( Hiejima, K; Satake, S; Suzuki, F; Takahashi, M, 1983) |
| "We evaluated the electrophysiologic effects of disopyramide phosphate in 12 patients with the Wolff-Parkinson-White syndrome." | 3.66 | Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome. ( Cook, L; Gallagher, JJ; Kerr, CR; Prystowsky, EN; Smith, WM, 1982) |
| "The efficacy of intravenous disopyramide was studied during 200 episodes of supraventricular and ventricular arrhythmias in 160 patients, mainly presenting with acute myocardial infarction or cardiac failure." | 3.66 | Efficacy of intravenous disopyramide in acute cardiac arrhythmias. ( De Backer, M; Kahn, RJ; Stoupel, E, 1981) |
| "The effect of administration of disopyramide on the ventricular response to atrial fibrillation was studied in six patients with the Wolff-Parkinson-White syndrome." | 3.66 | Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. ( Bennett, DH, 1978) |
| "Disopyramide phosphate was administered intravenously to 57 patients with 60 episodes of arrhythmia (21 supraventricular and 39 ventricular) as a 2 mg/kg bolus." | 3.65 | The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate. ( Deano, DA; Ehsani, AI; Mautner, RK; Rosen, KM; Sherman, RH; Wu, D, 1977) |
| "Neutropenia was the major toxicity (grade 4, 67%)." | 2.72 | Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. ( Fujii, S; Hamada, A; Kishi, H; Matsunaga, Y; Mori, I; Okamoto, I; Saito, H; Sasaki, J; Semba, H; Uramoto, H; Yamagata, H, 2006) |
| "The probability of absence of recurrence at 6 months was 36 +/- 11% in Group C and 55 +/- 10% in Group D (p = NS)." | 2.69 | [A randomized double-blind trial comparing cibenzoline and disopyramide in the prevention of recurrences of atrial tachyarrhythmia]. ( Baudouy, Y; Bine-Scheck, F; Cheikel, J; Dambrine, P; Flammang, D; Graux, P; Jouannon, C; Leenhardt, A; Piot, O, 1998) |
| "Antiarrhythmic therapy was chosen for 3-7 days by modified chronic electrophysiological study at three stages: (1) the efficacy of a drug, its action onset and termination were defined; (2) a dosage was chosen on an individual basis and the duration of drug potency was specified; (3) the dosage regimen of a drug given as a course therapy was confirmed by the results of trials." | 2.67 | [Evaluation of the possibility of selection of individual anti-arrhythmia therapy]. ( Antonchenko, IV; Borisova, EV; Chekhov, AM; Gimrikh, EO; Plekhanov, IG; Popov, SV; Savenkova, GM, 1991) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "Drug treatment of hypertrophic cardiomyopathy is the first-line treatment, at the onset of clinical signs and symptoms." | 1.35 | [Drug treatment for hypertrophic cardiomyopathy]. ( Gibelin, P, 2009) |
| "Disopyramide was first infused intravenously at 1 mg kg-1 for 5 min followed by a continuous infusion at 0." | 1.28 | Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White syndrome. ( Aihara, N; Kamakura, S; Kurita, T; Matsuhisa, M; Ohe, T; Shimizu, W; Shimomura, K; Takaki, H, 1992) |
| "Disopyramide was given to 5 patients resulting in suppression of the arrhythmia and relief of symptoms." | 1.26 | Atrial bigeminy with block associated with bradycardia and paroxysmal atrial fibrillation -- an important variant of the tachycardia-bradycardia syndrome. ( Camm, AJ; Spurrell, RA; Ward, DE; Washington, HG, 1979) |
| "In the treatment of extrasystole, the arrhythmia was eliminated or reduced by 75% in 15 of 23 patients." | 1.26 | [Oral longterm therapy with disopyramide phosphate in patients with atrial and ventricular arrhythmias (author's transl)]. ( Grewe, N; Stauch, M, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 58 (49.57) | 18.7374 |
| 1990's | 33 (28.21) | 18.2507 |
| 2000's | 22 (18.80) | 29.6817 |
| 2010's | 3 (2.56) | 24.3611 |
| 2020's | 1 (0.85) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, J | 1 |
| Zhu, Y | 1 |
| Lo, A | 1 |
| Gao, M | 1 |
| Lu, Y | 1 |
| Zhao, J | 1 |
| Zhang, H | 1 |
| Hirose, K | 1 |
| Yamaguchi, H | 1 |
| Oshima, Y | 1 |
| Choraku, M | 1 |
| Hirono, A | 1 |
| Takamori, N | 1 |
| Tamura, K | 1 |
| Mizobuchi, M | 1 |
| Enjoji, Y | 1 |
| Yamamoto, R | 1 |
| Ono, T | 1 |
| Funatsu, A | 1 |
| Kambayashi, D | 1 |
| Kobayashi, T | 1 |
| Nakamura, S | 3 |
| Gibelin, P | 1 |
| Miyakoshi, M | 1 |
| Ikeda, T | 1 |
| Miwa, Y | 1 |
| Sakaki, K | 1 |
| Ishiguro, H | 1 |
| Abe, A | 1 |
| Tsukada, T | 1 |
| Mera, H | 1 |
| Yusu, S | 1 |
| Yoshino, H | 1 |
| Komatsu, T | 3 |
| Tachibana, H | 1 |
| Satoh, Y | 1 |
| Ozawa, M | 1 |
| Kunugita, F | 1 |
| Tashiro, A | 1 |
| Okabayashi, H | 1 |
| Nakamura, M | 1 |
| Moers, AM | 1 |
| Scherlag, BJ | 1 |
| Niu, G | 1 |
| Lu, Z | 1 |
| Ghias, M | 1 |
| Lazzara, R | 1 |
| Jackman, WM | 1 |
| Po, SS | 1 |
| Abe, M | 1 |
| Maruyama, T | 2 |
| Fujii, Y | 1 |
| Kitai, M | 1 |
| Okada, K | 1 |
| Matsumoto, K | 2 |
| Soma, M | 1 |
| Shirayama, T | 3 |
| Shiraishi, H | 1 |
| Yoshida, S | 3 |
| Matoba, Y | 1 |
| Imai, H | 1 |
| Nakagawa, M | 4 |
| Suzuki, O | 2 |
| Yomogida, K | 2 |
| Horiuchi, D | 2 |
| Abe, N | 2 |
| Kameda, K | 2 |
| Owada, S | 2 |
| Tomita, H | 2 |
| Oikawa, K | 2 |
| Okumura, K | 2 |
| VerNooy, RA | 1 |
| Mounsey, JP | 1 |
| Eleftheriadis, D | 1 |
| Panagiotis, V | 1 |
| Eleftheriadis, N | 1 |
| Anzawa, R | 2 |
| Ishikawa, S | 2 |
| Tanaka, Y | 2 |
| Okazaki, F | 2 |
| Mochizuki, S | 2 |
| Okamoto, I | 1 |
| Hamada, A | 1 |
| Matsunaga, Y | 1 |
| Sasaki, J | 1 |
| Fujii, S | 1 |
| Uramoto, H | 1 |
| Yamagata, H | 1 |
| Mori, I | 1 |
| Kishi, H | 1 |
| Semba, H | 1 |
| Saito, H | 1 |
| Scharf, C | 1 |
| Sugiura, H | 1 |
| Chinushi, M | 1 |
| Komura, S | 1 |
| Hirono, T | 1 |
| Aizawa, Y | 1 |
| Malik, A | 1 |
| Ali, SS | 1 |
| Rahmatullah, A | 1 |
| Leclercq, JF | 1 |
| Georgiopoulos, G | 1 |
| Halkidis, H | 1 |
| Attuel, P | 1 |
| Maisonblanche, P | 1 |
| Coumel, P | 1 |
| Theisen, K | 1 |
| Prystowsky, EN | 2 |
| De Backer, M | 1 |
| Stoupel, E | 1 |
| Kahn, RJ | 1 |
| Zhivoderov, VM | 1 |
| Zakharov, VN | 1 |
| Doshchitsin, VL | 1 |
| Aksenova, TN | 1 |
| Andriukova, EI | 1 |
| Lloyd, EA | 1 |
| Gersh, BJ | 1 |
| Forman, R | 1 |
| Stewart, DE | 1 |
| Ikram, H | 1 |
| Przedlacki, J | 1 |
| Antonelli, D | 1 |
| Koltun, B | 1 |
| Barzilay, J | 1 |
| Kerr, CR | 1 |
| Smith, WM | 1 |
| Cook, L | 1 |
| Gallagher, JJ | 1 |
| Hiejima, K | 1 |
| Suzuki, F | 1 |
| Takahashi, M | 1 |
| Satake, S | 1 |
| Rubin, IL | 1 |
| Frieden, J | 1 |
| Keren, A | 1 |
| Tzivoni, D | 1 |
| Gottlieb, S | 1 |
| Benhorin, J | 1 |
| Stern, S | 1 |
| Bauernfeind, RA | 2 |
| Swiryn, SP | 1 |
| Strasberg, B | 2 |
| Palileo, E | 1 |
| Scagliotti, D | 1 |
| Rosen, KM | 2 |
| Grosu, AA | 1 |
| Malakhov, VI | 1 |
| Smetnev, AS | 1 |
| Kito, Y | 1 |
| Ohara, K | 1 |
| Manabe, H | 1 |
| Kimura, E | 1 |
| Mashima, S | 1 |
| Tanaka, T | 1 |
| Grey, E | 1 |
| Silverman, DI | 1 |
| Inoue, M | 3 |
| Inoue, D | 3 |
| Ishibashi, K | 3 |
| Sakai, R | 3 |
| Asayama, J | 3 |
| Boudonas, G | 1 |
| Lefkos, N | 1 |
| Efthymiadis, AP | 1 |
| Styliadis, IG | 1 |
| Tsapas, G | 1 |
| Kumagai, K | 4 |
| Gondo, N | 2 |
| Matsuo, K | 1 |
| Annoura, M | 2 |
| Moroe, K | 1 |
| Nakashima, Y | 2 |
| Hiroki, T | 2 |
| Arakawa, K | 2 |
| Fujiki, A | 2 |
| Tani, M | 2 |
| Inoue, H | 1 |
| Shimizu, A | 1 |
| Fukatani, M | 1 |
| Tanigawa, M | 1 |
| Kaibara, M | 1 |
| Konoe, A | 1 |
| Isomoto, S | 1 |
| Centurion, OA | 1 |
| Yano, K | 1 |
| Hashiba, K | 1 |
| Manz, M | 1 |
| Lüderitz, B | 2 |
| Koenig, A | 1 |
| Theolade, R | 1 |
| Chauvin, M | 1 |
| Brechenmacher, C | 1 |
| Omori, I | 1 |
| Yamahara, Y | 1 |
| van den Berg, MP | 1 |
| Haaksma, J | 1 |
| Brouwer, J | 1 |
| Crijns, HJ | 2 |
| Lie, KI | 2 |
| Gosselink, AT | 1 |
| Pernat, A | 1 |
| Pohar, B | 1 |
| Horvat, M | 1 |
| Hnatkova, K | 3 |
| Murgatroyd, FD | 3 |
| Guo, X | 3 |
| Camm, AJ | 4 |
| Malik, M | 3 |
| Watanabe, Y | 1 |
| Hara, Y | 1 |
| Tamagawa, M | 1 |
| Nakaya, H | 1 |
| Waktare, JE | 2 |
| Gallagher, MM | 1 |
| Piot, O | 1 |
| Flammang, D | 1 |
| Dambrine, P | 1 |
| Cheikel, J | 1 |
| Jouannon, C | 1 |
| Graux, P | 1 |
| Baudouy, Y | 1 |
| Bine-Scheck, F | 1 |
| Leenhardt, A | 1 |
| Kishikawa, T | 1 |
| Kaji, Y | 1 |
| Sasaki, Y | 1 |
| Kanaya, S | 1 |
| Fujino, T | 1 |
| Niho, Y | 1 |
| Ishihara, Y | 1 |
| Kubara, I | 1 |
| Ikeda, H | 2 |
| Hiraki, T | 2 |
| Yoshida, T | 1 |
| Ohga, M | 1 |
| Imaizumi, T | 2 |
| Iida, H | 1 |
| Morita, T | 1 |
| Suzuki, E | 1 |
| Iwasawa, K | 1 |
| Toyo-oka, T | 1 |
| Nakajima, T | 1 |
| Schumacher, B | 1 |
| Jung, W | 1 |
| Schmidt, H | 1 |
| Fischenbeck, C | 1 |
| Lewalter, T | 1 |
| Hagendorff, A | 1 |
| Omran, H | 1 |
| Wolpert, C | 1 |
| Nakazawa, H | 2 |
| Lythall, DA | 1 |
| Noh, J | 2 |
| Ishikawa, N | 3 |
| Sugino, K | 1 |
| Ito, K | 3 |
| Hardman, SM | 1 |
| Kaji, T | 1 |
| Nojima, Y | 1 |
| Arisaka, H | 1 |
| Naruse, T | 1 |
| Niwano, S | 1 |
| Kitano, Y | 1 |
| Moriguchi, M | 1 |
| Izumi, T | 1 |
| Abe, H | 1 |
| Nakashima, H | 1 |
| Oginosawa, Y | 1 |
| Saku, K | 2 |
| Yamanouchi, Y | 2 |
| Reynolds, RM | 1 |
| Walker, JD | 1 |
| Donaldson, RM | 1 |
| Dreifus, LS | 1 |
| Spurrell, RA | 3 |
| Thorburn, CW | 1 |
| Camm, J | 2 |
| Sowton, E | 1 |
| Deuchar, DC | 1 |
| Jennings, G | 1 |
| Jones, MS | 1 |
| Besterman, EM | 1 |
| Model, DG | 1 |
| Turner, PP | 1 |
| Kidner, PH | 1 |
| Breithardt, G | 1 |
| Haerten, K | 1 |
| Seipel, L | 1 |
| McHaffie, DJ | 1 |
| Guz, A | 1 |
| Johnston, A | 1 |
| Perroni, GB | 1 |
| Briguglio, FS | 1 |
| Oddo, A | 1 |
| Trovato, G | 1 |
| Meinertz, T | 1 |
| Langer, KH | 1 |
| Kasper, W | 1 |
| Just, H | 1 |
| Stauch, M | 1 |
| Grewe, N | 1 |
| Johnson, N | 1 |
| Martin, ND | 1 |
| Strathdee, G | 1 |
| Washington, HG | 1 |
| Ward, DE | 1 |
| Erbersdobler, O | 1 |
| Forester, D | 1 |
| Hayes, JG | 1 |
| Ward, D | 1 |
| Hoffmann, RM | 1 |
| Bennett, DH | 1 |
| LaBarre, A | 1 |
| Strauss, HC | 1 |
| Scheinman, MM | 1 |
| Evans, GT | 1 |
| Bashore, T | 1 |
| Tiedeman, JS | 1 |
| Wallace, AG | 1 |
| Rullière, R | 1 |
| Vial, F | 1 |
| Pornin, M | 1 |
| Jutzy, RV | 1 |
| Deano, DA | 1 |
| Wu, D | 1 |
| Mautner, RK | 1 |
| Sherman, RH | 1 |
| Ehsani, AI | 1 |
| Laidlaw, JC | 1 |
| Fowler, NO | 1 |
| Dean, RR | 1 |
| Befeler, B | 1 |
| Castellanos, A | 1 |
| Wells, DE | 1 |
| Vagueiro, MC | 1 |
| Yeh, BK | 1 |
| Sasayama, S | 1 |
| Shite, J | 1 |
| Yokota, Y | 1 |
| Nakatani, M | 1 |
| Takeuchi, Y | 1 |
| Tsumura, Y | 1 |
| Kawai, H | 1 |
| Ueno, H | 1 |
| Kawashima, T | 1 |
| Honda, Y | 1 |
| Fomina, IG | 2 |
| Iankin, VV | 1 |
| Shimizu, W | 1 |
| Ohe, T | 1 |
| Kurita, T | 1 |
| Takaki, H | 1 |
| Aihara, N | 1 |
| Kamakura, S | 1 |
| Matsuhisa, M | 1 |
| Shimomura, K | 1 |
| Villani, R | 1 |
| Zoletti, F | 1 |
| Veniani, M | 1 |
| Locati, F | 1 |
| Nava, S | 1 |
| Asano, Y | 1 |
| Saito, J | 1 |
| Kaneko, K | 1 |
| Yamamoto, T | 1 |
| Uchida, M | 1 |
| Antonchenko, IV | 1 |
| Gimrikh, EO | 1 |
| Popov, SV | 1 |
| Chekhov, AM | 1 |
| Borisova, EV | 1 |
| Savenkova, GM | 1 |
| Plekhanov, IG | 1 |
| Karlson, BW | 2 |
| Torstensson, I | 2 |
| Abjörn, C | 2 |
| Kallryd, A | 1 |
| Jonsson, J | 1 |
| Jansson, SO | 2 |
| Peterson, LE | 2 |
| Sugimoto, T | 1 |
| Yoshimoto, M | 1 |
| Yashiro, T | 1 |
| Ozaki, O | 2 |
| Kushakovskiĭ, MS | 1 |
| Grishkin, IuN | 1 |
| Ito, M | 1 |
| Onodera, S | 1 |
| Hashimoto, J | 1 |
| Noshiro, H | 1 |
| Shinoda, S | 1 |
| Nagashima, M | 1 |
| Suzuki, H | 1 |
| Fujimura, O | 1 |
| Klein, GJ | 2 |
| Sharma, AD | 2 |
| Yee, R | 2 |
| Szabo, T | 1 |
| Bauman, JL | 1 |
| Gallastegui, J | 1 |
| Swiryn, S | 1 |
| Hoff, J | 1 |
| Welch, WJ | 1 |
| Martin, A | 1 |
| Benbow, LJ | 1 |
| Leach, C | 1 |
| Bailey, RJ | 1 |
| Lundström, T | 1 |
| Rydén, L | 1 |
| Smolenskiĭ, VS | 1 |
| Abunder, AA | 1 |
| Kulikova, LA | 1 |
| Vasil'eva, VL | 1 |
| Guiraudon, G | 1 |
| Nakazawa, HK | 1 |
| Handa, S | 1 |
| Nakamura, Y | 1 |
| Oyanagi, H | 1 |
| Hasegawa, M | 1 |
| Bajaj, A | 1 |
| Patel, JS | 1 |
| Gavaghan, TP | 2 |
| Feneley, MP | 1 |
| Campbell, TJ | 2 |
| Morgan, JJ | 2 |
| Bertrix, L | 1 |
| Timour Chah, Q | 1 |
| Lang, J | 1 |
| Lakhal, M | 1 |
| Bouzouita, K | 1 |
| Faucon, G | 1 |
| Lisin, N | 1 |
| Andriange, M | 1 |
| Vandenbosch, R | 1 |
| Carlier, J | 1 |
| Härtel, G | 1 |
| Louhija, A | 1 |
| Konttinen, A | 1 |
| Pellegrino, L | 1 |
| Prencipe, D | 1 |
6 reviews available for disopyramide and Atrial Fibrillation
| Article | Year |
|---|---|
Disopyramide-induced hypoglycemia in a non-diabetic hemodialysis patient: a case report and review of the literature.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Female; Humans; Hypoglycemia; Polyp | 2011 |
Antiarrhythmic drug therapy of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Flecainide; Humans; Phenethyl | 2004 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
Pharmacologic therapy of tachyarrhythmias in patients with Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Ajmaline; Amiodarone; Anilides; Aprindine; Atr | 1983 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
[Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Disopyramide; El | 1993 |
30 trials available for disopyramide and Atrial Fibrillation
| Article | Year |
|---|---|
Prospective comparative study of intravenous cibenzoline and disopyramide therapy in the treatment of paroxysmal atrial fibrillation after cardiovascular surgery.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Surgi | 2010 |
Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Area Under Curve; Atrial Fibrillation; Carcinoma, Non-S | 2006 |
The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Clinical Trials as Topic; Disopyramide; Double-Blind M | 1984 |
Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Diltiazem; Disopyramide; Electrocardiogr | 1995 |
Effects of disopyramide on the atrial fibrillation threshold in the human atrium.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Disopyramide; Electrophys | 1995 |
Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Disopyramide; Do | 1996 |
Graphical representation of complex data--diurnal patterns of initiations of atrial fibrillation episodes.
Topics: Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Circadian Rhythm; Computer Graphics; Cross-Ov | 1997 |
Age and gender influences on rate and duration of paroxysmal atrial fibrillation.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Cross-Over Studies; Digoxi | 1998 |
Evolution of changes in the ventricular rhythm during paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Cross-Over Studies; Digoxin; Disopyramide; Do | 1998 |
[A randomized double-blind trial comparing cibenzoline and disopyramide in the prevention of recurrences of atrial tachyarrhythmia].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Double-Blind Method; Female; Humans | 1998 |
Effects of oral repetitive loading of disopyramide on acute-onset atrial fibrillation with concurrent monitoring of serum drug concentration.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disop | 1999 |
Clinical pharmacokinetics and effects of an oral sustained-release preparation of disopyramide prescribed for patients undergoing maintenance hemodialysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined | 2000 |
Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2000 |
Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction.
Topics: Administration, Oral; Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials as Topic; Disopyram | 1976 |
[Antiarrhythmic effect of disopyramide in ventricular extrasystole and auricular fibrillation].
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Cardiac Complexes, Premature; Disopyramide; Electrocar | 1976 |
[Disopyramide-dihydrogen phosphate (Rythmodul) in auricular fibrillation].
Topics: Adult; Aged; Atrial Fibrillation; Capsules; Clinical Trials as Topic; Disopyramide; Female; Humans; | 1978 |
[Decrease in auricular fibrillations by use of disopyramide. 70 trials].
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Disopyramide; Female; He | 1976 |
Clinical studies of Norpace (Part IV).
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials as T | 1975 |
Clinical studies of Norpace (Part VIII).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials as Topic; D | 1975 |
Clinical studies of Norpace. Summarizing remarks.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; At | 1975 |
[Prospective course of therapy arresting attacks of atrial fibrillation in patients with preexcitation syndromes].
Topics: Adult; Aged; Aged, 80 and over; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 1992 |
[A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation].
Topics: Amiodarone; Analysis of Variance; Atrial Fibrillation; Delayed-Action Preparations; Disopyramide; Fo | 1992 |
[Evaluation of the possibility of selection of individual anti-arrhythmia therapy].
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Humans; Middle Aged; P | 1991 |
[Preventive disopyramide after electroconversion of atrial fibrillation--a good alternative].
Topics: Adult; Aged; Atrial Fibrillation; Disopyramide; Double-Blind Method; Electric Countershock; Female; | 1991 |
Efficacy of disopyramide in conversion and prophylaxis of post-thyrotoxic atrial fibrillation.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Disopyramide; Electric Countershock; Humans; Premedica | 1991 |
Comparison of amiodarone and disopyramide in the control of paroxysmal atrial fibrillation and atrial flutter (interim report).
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Disopyramide; Female; Humans; Ma | 1986 |
Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study.
Topics: Adult; Aged; Atrial Fibrillation; Clinical Trials as Topic; Combined Modality Therapy; Delayed-Actio | 1988 |
[Place of disopyramide in relieving ectopic arrhythmia].
Topics: Adult; Aged; Atrial Fibrillation; Clinical Trials as Topic; Disopyramide; Humans; Middle Aged; Tachy | 1987 |
Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial.
Topics: Atrial Fibrillation; Atrial Flutter; Cardiopulmonary Bypass; Clinical Trials as Topic; Digoxin; Diso | 1985 |
Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Disopyramide; El | 1974 |
81 other studies available for disopyramide and Atrial Fibrillation
| Article | Year |
|---|---|
In Silico Assessment of Class I Antiarrhythmic Drug Effects on
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Computer Simulation; Dis | 2021 |
Severe respiratory failure and torsades de pointes induced by disopyramide in a patient with myasthenia gravis.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cholinergic Antagonists; Disopyramide; Electrocardiogra | 2008 |
Nifekalant and disopyramide in a patient with short QT syndrome: evaluation of pharmacological effects and electrophysiological properties.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Body Surface Potential Mapping; Disopyramide; Humans; M | 2008 |
[Drug treatment for hypertrophic cardiomyopathy].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiomyop | 2009 |
Quantitative assessment of cibenzoline administration for vagally mediated paroxysmal atrial fibrillation using frequency-domain heart rate variability analysis.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cholinergic Antagonists; Disopyramide; Electrocardiogra | 2009 |
Pharmacological prevention and termination of focal atrial fibrillation.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atrial Appendage; Atria | 2012 |
Atrial fibrillation threshold predicted long-term efficacy of pharmacological treatment of patients without structural heart disease.
Topics: Aged; Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Disopyramide; Electrophysiologic Techn | 2002 |
[Comparison of the efficacies of disopyramide, cibenzoline and aprindine for the termination of paroxysmal and persistent atrial fibrillation in elderly and non-elderly patients].
Topics: Aged; Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Autonomic Nervous System; Circadian Rh | 2003 |
[Relationship between duration of arrhythmia and subsequent preventive effect of disopyramide after cardioversion in patients with symptomatic paroxysmal and persistent atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Disopyramide; Electric Coun | 2003 |
Recurrent syncopic episodes as a consequence of combined Brugada syndrome and paroxysmal atrial fibrillation. Which is the therapy of choice?
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Disopyramide; Female; Humans | 2004 |
Atrial fibrillation: rate control often better than rhythm control.
Topics: Adult; Aged; Amiodarone; Anticoagulants; Arrhythmia, Sinus; Atrial Fibrillation; Canada; Disopyramid | 2004 |
Atrial pacing failure following termination of atrial fibrillation by acute administration of disopyramide phosphate.
Topics: Aged; Atrial Fibrillation; Cardiac Pacing, Artificial; Combined Modality Therapy; Disopyramide; Dose | 2005 |
Heart rate variability is a useful parameter for evaluation of anticholinergic effect associated with inducibility of atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cholinergic Antagonists; Disopyramide; Dogs; E | 2005 |
Deglutition-induced atrial fibrillation.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Deglutition; Disopyramide; Drug Therapy, Combina | 2005 |
Increased AAI mode pacing threshold after termination of atrial fibrillation by acute administration of disopyramide phosphate.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Disopyramide; Female; | 2006 |
[Effects of anti-arrhythmia agents on heart rate. Significance and importance].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 1981 |
[Pharmacotherapy of paroxysmal tachycardia].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Digitalis Glycosides; Disopyramide | 1983 |
Efficacy of intravenous disopyramide in acute cardiac arrhythmias.
Topics: Acute Disease; Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; C | 1981 |
[Anti-arrhythmic effectiveness of ethmozine, cordaron and rhythmodan in treating ischemic heart disease].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzofurans; Cardiac Complexes | 1981 |
The use of intravenous disopyramide for the conversion of supraventricular tachyarrhythmias.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Disopyramide; Dr | 1984 |
[Anuria in a patient treated with disopyramide for paroxysmal auricular fibrillation].
Topics: Aged; Anuria; Atrial Fibrillation; Disopyramide; Female; Humans | 1983 |
Acute hepatotoxic effect of disopyramide.
Topics: Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Disopyramide; Female; Humans; Middle Ag | 1984 |
Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Adolescent; Adult; Atrial Fibrillation; Disopyramide; Electrocardiography; Fem | 1982 |
Electrophysiologic evaluation of antiarrhythmic drugs on supraventricular tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Disopyramide; El | 1983 |
Electrocardiograms of the month. Arrhythmia.
Topics: Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Disopyramide; Electrocardiography; Female; Heart; H | 1980 |
Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.
Topics: Adult; Amiodarone; Atrial Fibrillation; Benzofurans; Disopyramide; Dose-Response Relationship, Drug; | 1982 |
Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: technique, application, and efficacy in severely symptomatic preexcitation patients.
Topics: Administration, Oral; Adolescent; Adult; Aprindine; Atrial Fibrillation; Cardiac Pacing, Artificial; | 1982 |
[Electrophysiological action of disopyramide].
Topics: Adolescent; Adult; Atrial Fibrillation; Cardiac Catheterization; Disopyramide; Drug Evaluation; Elec | 1982 |
[Postoperative treatment of acquired valvular disease with atrial fibrillation with disopyramide--with special reference to prevention of recurrence of atrial fibrillation].
Topics: Adult; Atrial Fibrillation; Disopyramide; Heart Valve Diseases; Humans; Middle Aged; Premedication; | 1982 |
Clinical evaluation of antiarrhythmic effects of disopyramide by multiclinical controlled double-blind methods.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Disopyramide; Double-Blind Method; Drug Evaluation; Human | 1980 |
Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Encainide; Female; Flecainide; Hear | 1993 |
Effects of E-4031 on atrial fibrillation threshold in guinea pig atria: comparative study with class I antiarrhythmic drugs.
Topics: Acetylcholine; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Disopyramide; | 1994 |
Wavelength index: a predictor of the response to disopyramide in paroxysmal lone atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Cardiac Pacing, Artificial; Disopyramide; Elect | 1994 |
Efficacy of class Ia antiarrhythmic drugs in converting atrial fibrillation unassociated with organic heart disease and their relation to atrial electrophysiologic characteristics.
Topics: Adult; Aged; Atrial Fibrillation; Cardiac Pacing, Artificial; Disopyramide; Electrophysiology; Femal | 1994 |
Mechanism of the suppression of repetitive atrial firing by isoproterenol--comparison with disopyramide.
Topics: Adult; Atrial Fibrillation; Atrial Function; Disopyramide; Electric Stimulation; Electrocardiography | 1994 |
Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Electrophysiology; Female; Fleca | 1993 |
Analysis of heart rate variability in a patient with paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Electrocardiography; Heart Rate; Humans; | 1995 |
Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Dis | 1997 |
Pirmenol inhibits muscarinic acetylcholine receptor-operated K+ current in the guinea pig heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbachol; Disopyramide; El | 1997 |
Dispersion of filtered P wave duration by P wave signal-averaged ECG mapping system: its usefulness for determining efficacy of disopyramide on paroxysmal atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Surface Potenti | 1999 |
Hypoglycemia induced by interaction between clarithromycin and disopyramide.
Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Atrial Fibrillation; Clarithromycin; Disopyramide; Dr | 1999 |
Transverse conduction capabilities of the crista terminalis in patients with atrial flutter and atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Disop | 1999 |
Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Electric Countershock; Femal | 2000 |
Transient appearance of antegrade conduction via an AV accessory pathway caused by atrial fibrillation in a patient with intermittent Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Electrocardiography | 2000 |
[Electrophysiological mechanism of combination therapy with disopyramide and propranolol for paroxysmal atrial fibrillation].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Drug Therapy, Combination; E | 2000 |
Hypoglycaemia induced by disopyramide in a patient with Type 2 diabetes mellitus.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus, Type 2; Disopyramide; Drug The | 2001 |
The treatment of supraventricular arrhythmias.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Arrhyt | 1979 |
Clinical studies of Norpace (Part X).
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes | 1975 |
Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Atrial Fibrillation; Atrioventricular Node; Cardiac Complexes, Premature; Child; | 1975 |
Impotence in patient on disopyramide.
Topics: Atrial Fibrillation; Disopyramide; Erectile Dysfunction; Humans; Male; Middle Aged; Pyridines | 1977 |
[Data on disopyridamide therapy of some arrhythmias].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; Disopyramid | 1977 |
Disopyramide-induced intrahepatic cholestasis.
Topics: Adult; Atrial Fibrillation; Cholestasis; Disopyramide; Female; Humans; Pyridines | 1977 |
[Oral longterm therapy with disopyramide phosphate in patients with atrial and ventricular arrhythmias (author's transl)].
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Di | 1977 |
Epileptiform convulsion with intravenous disopyramide.
Topics: Aged; Atrial Fibrillation; Disopyramide; Drug Evaluation; Epilepsy, Tonic-Clonic; Female; Humans; In | 1978 |
Atrial bigeminy with block associated with bradycardia and paroxysmal atrial fibrillation -- an important variant of the tachycardia-bradycardia syndrome.
Topics: Adult; Aged; Atrial Fibrillation; Bradycardia; Cardiac Complexes, Premature; Disopyramide; Electroca | 1979 |
Treatment of arrhythmias in the Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Atrial Fibrillation; Disopyramide; Humans; Injections, Intravenous; Lidocaine; | 1979 |
Disopyramide.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Disopyramide; Humans; Male; Middle Aged; Pyridines | 1979 |
The effect of intravenous disopyramide phosphate on recurrent paroxysmal tachycardias.
Topics: Atrial Fibrillation; Atrial Flutter; Blood Pressure; Disopyramide; Electrocardiography; Humans; Infu | 1979 |
Wolff-Parkinson-White syndrome. Evaluation of a potentially life threatening situation.
Topics: Adult; Atrial Fibrillation; Digoxin; Disopyramide; Humans; Male; Organophosphorus Compounds; Refract | 1978 |
Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Disopyramide; Female; Heart Ventricles; Huma | 1978 |
Electrophysiologic effects of disopyramide phosphate on sinus node function in patients with sinus node dysfunction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular Node; Bradycardia; Cardiac | 1979 |
The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Disopy | 1977 |
The pharmacology of Norpace.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atrioven | 1975 |
Electrophysiologic effects of the antiarrhythmic agent disopyramide phosphate.
Topics: Adult; Age Factors; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Bundle-Branch Block; Coronary D | 1975 |
[Evaluation of drug efficacy for preventing paroxysmal atrial fibrillation].
Topics: Adult; Aged; Atrial Fibrillation; Cardiac Pacing, Artificial; Disopyramide; Drug Evaluation; Electro | 1992 |
[Clinical and echocardiographic evaluation of the effects of atrial defibrillation in patients with idiopathic cardiomyopathy].
Topics: Adult; Atrial Fibrillation; Blood Pressure; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; D | 1992 |
Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Disopyramide; Dose-Response Relationship, Dr | 1992 |
On the mechanism of termination and perpetuation of atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Disopyramide; Electrocardiography; Female; Humans; Male; Middle Ag | 1992 |
Effects of transcatheter cardioversion on chronic lone atrial fibrillation.
Topics: Atrial Fibrillation; Cardiac Catheterization; Cardiac Pacing, Artificial; Chronic Disease; Disopyram | 1991 |
[Dissociated (dissimilar) atrial rhythms after administration of ritmilen].
Topics: Atrial Fibrillation; Atrial Flutter; Disopyramide; Electrocardiography; Female; Humans; Middle Aged | 1990 |
Effect of disopyramide on initiation of atrial fibrillation and relation to effective refractory period.
Topics: Atrial Fibrillation; Cardiac Pacing, Artificial; Disopyramide; Electrophysiology; Female; Heart Cond | 1989 |
Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Atrial Fibrillation; Disopyramide; Electrocardiography; Female; Humans; Male; Mid | 1989 |
Long-term therapy with disopyramide phosphate: side effects and effectiveness.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Disopyramide; Drug Tolerance; El | 1986 |
Chronic atrial fibrillation. Long-term results of direct current conversion.
Topics: Adult; Aged; Atrial Fibrillation; Chronic Disease; Disopyramide; Electric Countershock; Female; Foll | 1988 |
Sensitivity and specificity of invasive and noninvasive testing for risk of sudden death in Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Child; Death, Sudden; Disopyramide; Electrocardiograph | 1987 |
High maintenance rate of sinus rhythm after cardioversion in post-thyrotoxic chronic atrial fibrillation.
Topics: Adult; Atrial Fibrillation; Chronic Disease; Disopyramide; Electric Countershock; Electrocardiograph | 1987 |
Wolff-Parkinson and White syndrome. Clinical presentation and management.
Topics: Adult; Atrial Fibrillation; Disopyramide; Electrocardiography; Female; Humans; Male; Middle Aged; Wo | 1986 |
Atrial tachyarrhythmias after cardiac surgery: results of disopyramide therapy.
Topics: Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures; Digoxin; Disopyramide; Drug Therap | 1985 |
Efficacy of disopyramide in comparison with verapamil and propranolol in the prevention of acetylcholine-induced atrial fibrillation in the dog.
Topics: Acetylcholine; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressu | 1985 |
[Treatment of disturbances of cardiac rhythm using intravenous disopyramide].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Brad | 1974 |
[Disopyramide in the therapy and prevention of chronic atrial fibrillation. Study of 50 cases].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arteriosclerosis; Atrial Fibrillation; Coronary Disease; Disopy | 1973 |